Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Surgery, Fuchu Hospital, Osaka, Japan.
Anticancer Res. 2023 Nov;43(11):4823-4832. doi: 10.21873/anticanres.16679.
BACKGROUND/AIM: CD103 tissue-resident memory T cells (T) in tumor sites are associated with a favorable prognosis and predict the effectiveness of immune checkpoint inhibitors. The detection of CD103 T infiltration in biopsy samples could be beneficial for patients without surgical indications. However, the usefulness of T detection in biopsy tissue and the difference in T status between biopsy and surgical specimens' post-neoadjuvant chemotherapy have not been elucidated. In the present study, we aimed to elucidate whether we can detect T in biopsy specimens and the impact of chemotherapy on T infiltration.
Tissue sections were obtained from 46 patients with esophageal cancer who received neoadjuvant chemotherapy and underwent radical esophagectomy in 2017. Immunohistochemistry was performed using an anti-CD103 antibody for biopsy and surgical specimens. We examined the relationship between CD103 expression, clinicopathological features, and prognosis for each patient.
T infiltration was detected in the biopsy specimens. CD103 expression in biopsy specimens correlated with that in surgical specimens. Although there was no statistical significance in clinicopathological findings between CD103high and CD103low, patients with CD103high biopsy specimens exhibited favorable prognosis. The number of CD103 cells was increased by chemotherapy: though with no survival benefit.
Regardless of surgical indication, we were able to determine the T status even in biopsy specimens. CD103 evaluation at biopsy may be more useful and practical than evaluation in surgical specimens, enabling prediction of prognosis and response to immune therapy.
背景/目的：肿瘤部位的 CD103 组织驻留记忆 T 细胞（T）与预后良好相关，并预测免疫检查点抑制剂的有效性。在没有手术指征的患者中，检测活检样本中的 CD103 T 浸润可能是有益的。然而，尚未阐明在活检组织中检测 T 的有用性以及新辅助化疗后活检和手术标本之间 T 状态的差异。在本研究中，我们旨在阐明是否可以在活检标本中检测到 T 以及化疗对 T 浸润的影响。
收集 2017 年接受新辅助化疗并接受根治性食管切除术的 46 例食管癌患者的组织切片。使用抗 CD103 抗体对活检和手术标本进行免疫组织化学染色。我们检查了每位患者的 CD103 表达与临床病理特征和预后之间的关系。
在活检标本中检测到 T 浸润。活检标本中 CD103 的表达与手术标本中的表达相关。尽管 CD103high 和 CD103low 之间的临床病理发现没有统计学意义，但 CD103high 活检标本的患者预后较好。尽管化疗并没有带来生存获益，但化疗增加了 CD103 细胞的数量。
无论是否有手术指征，我们都能够在活检标本中确定 T 状态。在活检时评估 CD103 可能比在手术标本中更有用和实用，能够预测预后和对免疫治疗的反应。
